Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma

Clinical Advances in Hematology and Oncology

Volumn 6, Issue 1, 2008, Pages 44-54

  Attia, Steven ^a   Holen, Kyle D ^a   Thomas, James P ^b   Richie, Kelly ^a   Dzelak, Torie ^a   Teeter, Kristine ^a   Warren, Deb ^a   Bilger, Andrea ^a   Fine, Jason ^a   Eickhoff, Jens ^a   Drinkwater, Norman ^a   Mulkerin, Daniel ^a   Morgan Meadows, Sherry ^c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Gulf Coast Minority Based Clinical Oncology Program   (United States)

Author keywords

Growth hormone; Hepatocellular carcinoma; Hepatoma; Insulin like growth factor; Octreotide

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CISPLATIN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GROWTH HORMONE; MITOXANTRONE; OCTREOTIDE; SHORT ACTING DRUG; SOMATOMEDIN B; SOMATOMEDIN C; THALIDOMIDE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ABDOMINAL CRAMP; ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; CHEMOEMBOLIZATION; CHILL; CHOLESTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COUGHING; CRYOTHERAPY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEMALE; FOOT PAIN; HORMONE BLOOD LEVEL; HUMAN; LIVER CELL CARCINOMA; LOG RANK TEST; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; RADIOFREQUENCY ABLATION; RIGOR; SATIETY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; URINARY FREQUENCY; VOMITING; WILCOXON SIGNED RANKS TEST; DELAYED RELEASE FORMULATION; DRUG EFFECT; KAPLAN MEIER METHOD; LIVER TUMOR; METASTASIS; MIDDLE AGED;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, HEPATOCELLULAR; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OCTREOTIDE; PROGNOSIS;

EID: 41449102603     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Bosch F, Ribes J, Cleries R and Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9:191-211.
2. Parkin D. Pisani P, Ferlay J. Estimates of the world incidence of 25 major cancer in 1990. Int J Cancer. 1999;80:827-841.
3. Parkin D, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin. 2005;55:7A-108.
4. El-Serag H, Mason A. Rising incidence of hepatocellular carcinoma in the United States. N Engl Med. 1999;340:745-750,
5. Edwards BK, Brown ML, Wingo PA, et al, Annual report to the nation on the status of cancer 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97:1407-1427.
6. The National Comprehensive Cancer Network. Hepatobiliary cancers. Clinical Practice Guidelines in Oncology 2006;v1.2006.
7. Richardson H, Griffin A., Rinfret A. Adrenal histological change and liver-tumor inhibition in hypophysectomized rats fed the azo dye, 3-methyl-4-dimethylaminoazobenzene. Cancer 1953;6:1025-1029.
8. Griffin AC. Richardson HL, Robertson CH, O'Neal MA, Spain JD. The role of hormones in liver carcinogenesis. J Natl Cancer Inst. 1955;15:1623-1631.
9. Robertson C, O'Neil M, Richardson H, Griffin A. Further observations on the role of die pituitary and the adrenal gland in azo dye carcinogenesis. Cancer Res. 1954;14:549-553.
10. Orian JM, Tamakoshi K, Mackay IR, Brandon MR. New marine model for hepatocellular carcinoma: transgenic mice expressing metallothionien-ovine growth hormone fusion gene. J Natl Cancer Inst. 1990;82:393-398.
11. Snibson KJ, Bharbal PS, Adams TE. Overexpressed growth hormone (GH) synergistically promoted carcinogen-initiated liver tumor growth by promoting cellular proliferation in emerging hepatocellular neoplasms in female and male GH transgenic mice. Liver. 2001;21:149-58.
12. Bugni J, Poole T, Drinkwater N. The little mutation suppresses DEN-induced hepatocarcinogenesis in mice and abrogates genetic and hormonal modulation of susceptibility. Carcinogenesis. 2001;22:1853-62.
13. Barzilay J, Heatley GJ, Cushing GW. Benign and malignant rumors in patients with acromegaly. Arc Int Med. 1991;151:1629-1632.
14. Nabarro JD. Acromegaly. Clin Endocrinol. 1987;26:481-512.
15. Bengtsson BA.Acromegaly. J Ped Endocrinal. 1993;6:73-78.
16. Popovic, V, Damjanovic S, Meic D, et al. Increased incidence of neoplasia in patients with pimitary adenomas: the Pituitary Study Group. Clin Endocrinol. 1998;49:441-445.
17. Jenkins PJ, Besser M. Clinical perspective: acromegaly and cancer: a problem J Clin Endocrinol Metabol. 2001:86:2935-2941.
18. Melmed S. 2001. Clinical perspective: acromegaly and cancer: a problem? J Clin Endocrinol Metabol. 2001:86:2935-2941.
19. Orme SM, McNally RJ, Cartwight RA, Belcherz PE. Mortality and cancer incidence in actomegaly: a retrospective cohort study. J Clin Endocrinol Metabol. 1998;83:2730-2734.
20. Salmela PI, Juustila H, Pyhtinen J, Jokinen K, Alavaikko M. Ruokonen A. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-1, and the amino-terminal propeptide of type III procollagen in actomegaly. J Clin Endocrinol Metab 1990;70:1193-201.
21. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Science. 1982;31:1133-1140.
22. Bevan J. Atkin S, Atkinson. A, et al. Primary medical therapy for acromegaly an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I and tumor size. J Clin Endocrinol Metab. 2002;87:4554-63.
23. Ho K, Weissberger A, Marbach P, Lazarus L. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octrentide) in acromegaly. Effects of dose and frequency and long-term safety. Ann Intern Med. 1990;112:173-81
24. Gillis JC, Noble S, Goa XL. Ocreotide long-acting release (LAR). A review subtype pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997;53:681-99.
25. Li Y, Si JM, Zharg J, Du J, Wang F. Jia B. Somatostatin receptor subtype 2-mediated scitigraphy and localization using (99m)Tc-HYNIC-Ty:3)-octreotide in human hepatocellular carcinoma bearing nude mice. Worid J Gastroenterol. 2005;11:3953-3957.
26. Reynaert H, Rombouts K, Vandermonde A, Urbain D, Kumar U. Bioulac-Sage P. Expression of somatostatin receptors in normal and cirrhotic human liver aud in hepatocellular carcinoma. Gut. 2004;53:1180-1189.
27. Blaker M, Schmitz M, Gocht A, Burghardt S, Schulz K Broring D. Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. J Hepatol. 2004;41:112-8.
28. Reubi JC, Zimmermann A, Jonas S, et al. Regulatory peptide receptors in human hepatocellular carcinomas. Gut. 1999;45:766-74.
29. Liu H. Huo L, Wang L. Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells. Acta Pharmacol Sin. 2004;25:1360-1386.
30. Jia W, Xu G, Xu R, et al. Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. J Cancer Res Clin Oncol. 2003;129:327-334.
31. Jia W, Xu G, Sun H, Wang L, Xu R, Xue Q. Effect of ocrreotide on angio-genesis induced by hepatocellular carcinoma in vivo. Hepatobiliary Pancreat Dis Int. 2003:2:404-409.
32. Chen X. Liu Z, AI Z. Antineoplastic mechanism of Octreotide action in human hepatoma. Chin Med. J 2001;114:1167-1170,
33. Kouroumalis E., Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos O. Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study. Gut, 1998;42:442-447.
34. Yuen M, Tung-Ping Poon R, Lai C, et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology. 2002;36:687-691.
35. Becker G, Allgaier HP, Olschewski M, Zähringer A, Blum HE; HECTOR Study Group. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology. 2007;45:9-15.
36. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, et al. The role of sand-ostatin LAR in treating patients with advanced hepatocellular cancer. Hepagastroenterology. 2002;49:1245-1250.
37. Lersch C, Schmelz R, Erdmann J, et al. Treatment of HCC with pravastatin, octreotide, or gemcirabine: a critical evaluation. Hepatogastroenterology, 2004;51:1099-1103.
38. Slijkhuis W, Stadheim L, Hassoun Z, et al. Octreotide therapy for advanced hepatoellular carcinoma. J Clin Gastroenterol. 2005;39:333-337.
39. Therasse F, Arbuck SG, Eisenhauer FA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000:92: 205-216.
40. Pugh R, Murray-Lyon I, Dawson J, Pietroni M, Williams R. Thansection of the oesophagus for bleeding oesophagus varices. Br J Surg. 1973;60:646-649.
41. Conn H. A peek at the Child-Turcoute classification. Hepatology. 1981;1.: 673-676.
42. The Cancer of Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology. 1998;28:751-755.
43. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment, Study of 850 patients, Cancer. 1985;56:918-28.
44. Chiaramonte M. Stroffolini T, Vian A, Stazi MA, Floreani A, Lorenzoni U. Rate of incidence of hepatocellular carcinoma in patients widi compensated viral cirrhosis. Cancer, 1999;85:2132-2137.
45. Watabe H, Shitatori Y, Tateishi R, et al. Clinical features of patients with HCC who are negativ6 for both HBV and HCV markers. Hepato-Gastroenterol. 2003;50:2157-2160.
46. Dhomen K, Shigematsu H, Irie K, Ishibashi H. Comparison of the clinical characteristics among hepatocellular carcinoma of hepatitis B, hepatitis C and non-B non-C pacients. Hepato-Gastroenterol. 2003;50:2022-2027.
47. Benvegnù L, Noventa F, Bernardinello E, Pontisso P, Gatta A, Alberti A. Evidence for association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut. 2001;48:10-115
48. Treiber G, Wex T, Röcken C, Fostitsch P, Malfertheiner P. Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006;132:699-708.
49. Cozzi R, Montini M, Artanasio, R, et al. Primary treatment of acromegaly with ocrreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab. 2006;91:1397-403.
50. Colao A, Pivonello, R, Rosato F, et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patienis with acromegaly: results front an open, prospective, multicentre trial. Clin Endocrinol (oxf). 2006;64:342-51.
51. Mise M, Arii S, Higashituji H, et al, Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology. 1996;23:455-64.
52. Ishii Y, Nakasato, Y, Kobayashi S, Ysmazaki Y, Aoki T. A study on angiogenesis-related matrix metalloproteinase networks in primary hepatocellular carcinoma, J Exp Cin Cancer Res. 2003;22:461-70.
53. Dupuy E, Hainaud P, Villemain. A, et al. Tumoral angiogenesis and tissue factor expression during hepatocellular carcinoma progression in a transgenic mouse model. J Hepatol. 2003;38:793-802.
54. Kim YB, Park YN, Park C. Increased prolileration activities of vascular endothelial cells and tumour cells in residual hepatocellular carcinoma following transcatheter arterial embolization. Histopathology. 2001;38:160-166.
55. Maxwell PH, Dadis GU, Gleadle JM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A. 1997;94:8104-8109.
56. von Marschall Z, Cramer T, Hocker M, Finkenzeller G. Wiedenmann B, Rosewicz S. Dual mechanism of vascular endothelial growth factor upregulation by hypaxia in human bepatocellular carcinoma. Gut. 2001;48:87-96.
57. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, et al. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of smarostatin receptors: randomized placebo-controlled trial. World J Gastroenterol. 2007;13:3164-3170.
58. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib improves survival in advanced hepatocellular Carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol. 2007;25(18S pt 1):LBA1.
59. Samonakis D, Moschandreas J, Arnaoutis T, et al. Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncol Rep. 2002;9:903-907.
60. Siveke J, Folwaczny, Herberhold C. Complete regression of advanced HCC with long acting ocotreotide. Gut. 2003;52:1531.
61. Deming D, Stella A, Holen K, Ku G, O'Reilly E. A dramatic response to long-acting octreotide in metastatic hepatocellular carcinoma. Clin Adv Hematol Oncol. 2005;3:468-472.
62. Rahmi G, Malka D, Tomasic G, Dromain C,Ducreux M, Boige V. Complete, long-standing regression of hepatocellular carrinoma after somatostatin analogue treatment. J Clin Oncol 2007;25(16):e15-e16.
63. Ye QH, Qin LX, Forgues M, et al. Predicting, hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling supervised machine learning. Nat Med. 2003;9:416-423.
64. Iizuka N, Oka M, Yamada-Okabe H, et al. Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method, Cancer Res. 2002;62:3939-3944.
65. Okabe H, Satoh S, Kato T et al. Genome-wide analysis of gene expression in human hepatoceltular carciriornas using cDNA microarray: identification of genes involved in viral carcinoge=sis and tumor progression. Cancer Res. 2001:61: 2129-2137.
66. Xu XR, Huang J, Xu ZG, et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci U S A. 2001;98:15089-15094.
67. Ai J, Tan Y, Ying W, et al. Proteome, analysis of hepatocellular carcinoma by laser capture microdissection. Proteomics. 2006;6:538-546.
68. Shen H, Cheng G. Fan H, et al. Expressed proteome analysis of human hepatocellular carcinoma in nude mice LCI-D20) with high metastasis potential. Proteomics. 2006;6:528-537.